Optibiotix names René Kamminga as CEO of subsidiary

Biotechnology company Optibiotix Health named René Kamminga as chief executive officer of its OptiBiotix Ltd subsidiary on Tuesday, subject to completion of normal regulatory due diligence.

Optibiotix said the appointment of Kamminga, formerly the chief commercial officer of KD Pharma's Nutraceuticals division, continued the evolution of its board and management team in line with its strategic focus on commercialising final products solutions and second-generation products.

The AIM-listed group added that Kamminga had experience in developing a business from selling bulk ingredients to finished product and a wealth of industry contacts in both the pharmaceutical and nutraceutical industries, as well as "a strong track record" of rapidly growing sales.

Elsewhere, Optibiotix said Dr Fred Narbel will move from his position as director on the OptiBiotix Health board and managing director of the functional fibres division of OptiBiotix Ltd to a more strategic role as non-executive director.

As of 1335 GMT, Optibiotix shares had dipped 0.23% to 51.88p.